| 
 | |||||
|   | 
| 
 | 

Financial software provider SS&C Technologies (NASDAQ:SSNC) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 5.9% year on year to $1.54 billion. The company expects next quarter’s revenue to be around $1.55 billion, close to analysts’ estimates. Its non-GAAP profit of $1.45 per share was 4.2% above analysts’ consensus estimates.
Is now the time to buy SSNC? Find out in our full research report (it’s free).
SS&C’s second quarter was marked by steady organic growth and strong contributions from its core fund administration and software-enabled services businesses. Management pointed to the GlobeOp segment’s double-digit growth in private markets and retail alternatives as a primary driver, supported by expanding client relationships in Europe, Australia, and the Middle East. CEO Bill Stone emphasized, “Internationally, we are seeing strength... reflecting a positive trend of increased international win rates attributable to the investments we have made over the past several years.” The company also maintained high client retention rates while continuing to invest in new technology and operational efficiency.
Looking ahead, SS&C leadership expects continued momentum from recently launched AI-driven solutions, ongoing international expansion, and their acquisition of Calastone. Management highlighted the opportunity to accelerate cross-selling with Calastone’s network and to leverage Blue Prism’s AI capabilities across more client workflows. CFO Brian Schell noted that the company will continue to prioritize R&D investments, stating, “We’re generating lots of cash... but we’re not going to starve our development teams.” The company is also closely monitoring macroeconomic factors and seasonal trends in its Healthcare and class action services businesses as it guides for steady full-year growth.
Management attributed second quarter growth to expanding international demand, AI-related product traction, and continued progress in fund administration and software-enabled services.
SS&C’s outlook centers on scaling AI solutions, cross-selling post-acquisition, and maintaining high client retention, while monitoring macroeconomic and seasonal sector dynamics.
Over the coming quarters, the StockStory team will be watching (1) the pace of cross-selling and integration with Calastone, (2) the scaling and commercialization of Blue Prism AI-driven solutions across new client segments, and (3) deal activity in Healthcare and class action services, especially as seasonal trends play out. Progress on these fronts will be key in assessing SS&C’s ability to sustain organic growth and margin expansion.
SS&C currently trades at $85.85, up from $83.63 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).
When Trump unveiled his aggressive tariff plan in April 2024, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.
Don’t let fear keep you from great opportunities and take a look at Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
| Oct-30 | |
| Oct-30 | |
| Oct-28 | |
| Oct-27 | |
| Oct-24 | |
| Oct-24 | |
| Oct-24 | |
| Oct-23 | |
| Oct-23 | |
| Oct-23 | |
| Oct-23 | |
| Oct-23 | |
| Oct-23 | |
| Oct-23 | |
| Oct-21 | 
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite